Cocrystal Pharma Inc (COCP) - Total Assets
Based on the latest financial reports, Cocrystal Pharma Inc (COCP) holds total assets worth $9.71 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See COCP net asset value for net asset value and shareholders' equity analysis.
Cocrystal Pharma Inc - Total Assets Trend (2007–2025)
This chart illustrates how Cocrystal Pharma Inc's total assets have evolved over time, based on quarterly financial data.
Cocrystal Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cocrystal Pharma Inc's total assets of $9.71 Million consist of 83.8% current assets and 16.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.3% |
| Accounts Receivable | $706.00K | 7.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Cocrystal Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cocrystal Pharma Inc (COCP) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cocrystal Pharma Inc's current assets represent 83.8% of total assets in 2025, an increase from 64.2% in 2007.
- Cash Position: Cash and equivalents constituted 72.3% of total assets in 2025, up from 64.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 7.3% of total assets.
Cocrystal Pharma Inc Competitors by Total Assets
Key competitors of Cocrystal Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Cocrystal Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.68 | 4.77 | 23.12 |
| Quick Ratio | 3.68 | 4.77 | 23.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.92 Million | $9.15 Million | $32.23 Million |
Cocrystal Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Cocrystal Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.29 |
| Latest Market Cap to Assets Ratio | 1.96 |
| Asset Growth Rate (YoY) | -27.8% |
| Total Assets | $9.71 Million |
| Market Capitalization | $19.02 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cocrystal Pharma Inc's assets above their book value (1.96x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cocrystal Pharma Inc's assets decreased by 27.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cocrystal Pharma Inc (2007–2025)
The table below shows the annual total assets of Cocrystal Pharma Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.71 Million | -27.82% |
| 2024-12-31 | $13.46 Million | -56.95% |
| 2023-12-31 | $31.26 Million | -23.46% |
| 2022-12-31 | $40.84 Million | -48.56% |
| 2021-12-31 | $79.39 Million | +46.37% |
| 2020-12-31 | $54.24 Million | +90.12% |
| 2019-12-31 | $28.53 Million | -58.39% |
| 2018-12-31 | $68.56 Million | -43.54% |
| 2017-12-31 | $121.43 Million | -2.77% |
| 2016-12-31 | $124.88 Million | -44.31% |
| 2015-12-31 | $224.23 Million | -13.52% |
| 2014-12-31 | $259.28 Million | +3915.99% |
| 2013-12-31 | $6.46 Million | -10.82% |
| 2012-12-31 | $7.24 Million | -4.07% |
| 2011-12-31 | $7.55 Million | +8343.98% |
| 2010-12-31 | $89.37K | -20.60% |
| 2009-12-31 | $112.55K | -17.97% |
| 2008-12-31 | $137.20K | -19.85% |
| 2007-12-31 | $171.18K | -- |
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C … Read more